Wall Street is positive on Oramed Pharmaceuticals, Inc. (ORMP). On average, analysts give ORMP a Hold rating. The average price target is $10.2, which means analysts expect the stock to rise by 365.75% over the next twelve months. That average ranking earns ORMP an Analyst Rating of 6, which is better than 6% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ORMP a Hold today. Find out what this means to you and get the rest of the rankings on ORMP!